Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Inclusion Criteria:

- Patients must have at least one measurable lesion at baseline by computed tomography
(CT) or magnetic resonance imaging (MRI) as per RECIST v1.1 criteria.

- Patients must have had progressive disease on, after, or refused, appropriate approved
therapy for their tumor type.

- Understand and sign an IRB/IEC-approved ICF prior to any study-specific evaluation

- ECOG performance status of 0 or 1

- Willing and able to comply with all study procedures

Exclusion Criteria:

- Current or history of clinically significant muscle disorders (e.g., myositis), recent
unresolved muscle injury, or any condition known to elevate serum CK levels

- Decreased cardiac function with NYHA > Class 2

- Uncontrolled or significant heart disorder such as unstable angina

- Significant abnormalities on ECG at screening. QTcF >450 msec for males or >470 msec
for females at screening

- History of anti-drug antibodies, severe allergic, anaphylactic, or other
infusion-related reaction to a previous biologic agent

- Positive test for latent tuberculosis (TB) at screening (Quantiferon test) or evidence
of active TB

- Patients with abnormal serum chemistry values, which in the opinion of the
Investigator is considered to be clinically significant, will be excluded from the
study

- Lack of peripheral venous or central venous access or any condition that would
interfere with drug administration or collection of study samples

- Any uncontrolled medical condition or psychiatric disorder which, in the opinion of
the Investigator, would pose a risk to patient safety or interfere with study
participation or interpretation of individual patient results

- Pregnant or breastfeeding

- Current unresolved infection or history of chronic, active, clinically significant
infection (viral, bacterial, fungal, or other) which, in the opinion of the
Investigator, would preclude the patient from exposure to a biologic agent or pose a
risk to patient safety

- Prior exposure to any CSF1R pathway inhibitors